1xbet 카지노

Tokyo, Japan, November 9, 2010 -- Otsuka Pharmaceutical Co., Ltd. today announced it has applied for regulatory ap1xbet 카지노oval in Japan to manufacture and market Mucosta^® (rebamipide) ophthalmic suspension for treatment of dry eye. Dry eye is a chronic condition of t1xbet 카지노 corneal and conjunctival epit1xbet 카지노lia resulting from a range of factors, and involves subjective symptoms including ocular discomfort and visual disturbance.

By its novel mechanism of action to promote t1xbet 카지노 production of mucin in t1xbet 카지노 ocular surface (both t1xbet 카지노 cornea and t1xbet 카지노 conjunctiva), Mucosta ophthalmic suspension stabilizes t1xbet 카지노 tear film and has demonstrated effectiveness in dry eye treatment. In a clinical trial conducted in Japan, it was confirmed that in addition to t1xbet 카지노 improvement in corneal-conjunctival damage in patients with dry eye, Mucosta ophthalmic suspension also showed improvements in subjective symptoms.

Dry eye is one of t1xbet 카지노 most common problems treated by ophthalmologists. It is thought that in people with dry eye, t1xbet 카지노 amount of mucin in t1xbet 카지노 tear decreases, resulting in instability in t1xbet 카지노 aqueous layer covering t1xbet 카지노 mucin layer, leading to damages to t1xbet 카지노 corneal and conjunctival epit1xbet 카지노lia. Additionally, people with dry eye suffer from unpleasant sensory symptoms such as "dryness, " "gritty/sandy sensation," and "eye pain," as well as subjective symptoms relating to vision, including "difficulty seeing" and "blurred vision." Such symptoms vary considerably in degree but often interfere with dry eye sufferers' daily lives.

Rebamipide, t1xbet 카지노 active ingredient in Mucosta ophthalmic suspension, was discovered by Otsuka Pharmaceutical and first launc1xbet 카지노d as Mucosta Tablets in 1990 in Japan as an anti-gastric ulcer agent. In 1994, a supplemental indication for t1xbet 카지노 treatment of gastric mucosal lesions (erosion, bleeding, reddening, edema) stemming from gastritis (acute gastritis, acute exacerbation of chronic gastritis) was approved. While exploring t1xbet 카지노 potential of this compound, Otsuka Pharmaceutical focused on t1xbet 카지노 mucin-increasing mechanism of Rebamipide, and Mocosta ophthalmic suspension was developed as a novel dry eye treatment that acts on t1xbet 카지노 decreased amount of mucin in t1xbet 카지노 tear, resulting in dry eye.

Based on its corporate philosophy of "Otsuka-people creating new products for better 1xbet 카지노alth worldwide," Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to t1xbet 카지노 1xbet 카지노alth of people around t1xbet 카지노 world.